** Shares in Elekta EKTAb.ST falls 5.5% after the Swedish
radiation therapy equipment maker reported a 9% decline in Q2
orders, while consensus cited by J.P.Morgan was expecting 1.5%
growth
** Adjusted EBIT falls 22% y/y to SEK 423 million ($38.57
million), 7.9% below consensus
** JPM says it expects cuts to EBIT consensus in the second
half of the year due to the Q2 miss
** The broker adds the improvement in orders from China and
the forecast for an H2 acceleration might not be enough to
convince investors
** The stock trades at its lowest level since December 2022
and is among the worst performers on the pan-European STOXX 600
.STOXX
($1 = 10.9671 Swedish crowns)
(Reporting by Anna Chaberska)
((Anna.chaberska@thomsonreuters.com))